Inhibition of JAK1/2 Tyrosine Kinases Reduces Neurogenic Heterotopic Ossification After Spinal Cord Injury.
Animals
Cells, Cultured
Disease Models, Animal
Immunohistochemistry
Janus Kinase 1
/ antagonists & inhibitors
Janus Kinase 2
/ antagonists & inhibitors
Janus Kinase Inhibitors
/ pharmacology
Mice
Monocytes
/ drug effects
Muscle Cells
Ossification, Heterotopic
/ drug therapy
Phosphorylation
STAT3 Transcription Factor
/ metabolism
Spinal Cord Injuries
/ drug therapy
X-Ray Microtomography
JAK- STAT signaling pathway
heterotopic ossification
oncostatin M receptor
ruxolitinib
spinal cord injury complications
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2019
2019
Historique:
received:
30
11
2018
accepted:
14
02
2019
entrez:
23
3
2019
pubmed:
23
3
2019
medline:
15
7
2020
Statut:
epublish
Résumé
Neurogenic heterotopic ossifications (NHO) are very incapacitating complications of traumatic brain and spinal cord injuries (SCI) which manifest as abnormal formation of bone tissue in periarticular muscles. NHO are debilitating as they cause pain, partial or total joint ankylosis and vascular and nerve compression. NHO pathogenesis is unknown and the only effective treatment remains surgical resection, however once resected, NHO can re-occur. To further understand NHO pathogenesis, we developed the first animal model of NHO following SCI in genetically unmodified mice, which mimics most clinical features of NHO in patients. We have previously shown that the combination of (1) a central nervous system lesion (SCI) and (2) muscular damage (via an intramuscular injection of cardiotoxin) is required for NHO development. Furthermore, macrophages within the injured muscle play a critical role in driving NHO pathogenesis. More recently we demonstrated that macrophage-derived oncostatin M (OSM) is a key mediator of both human and mouse NHO. We now report that inflammatory monocytes infiltrate the injured muscles of SCI mice developing NHO at significantly higher levels compared to mice without SCI. Muscle infiltrating monocytes and neutrophils expressed OSM whereas mouse muscle satellite and interstitial cell expressed the OSM receptor (OSMR).
Identifiants
pubmed: 30899259
doi: 10.3389/fimmu.2019.00377
pmc: PMC6417366
doi:
Substances chimiques
Janus Kinase Inhibitors
0
STAT3 Transcription Factor
0
Janus Kinase 1
EC 2.7.10.2
Janus Kinase 2
EC 2.7.10.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
377Références
J Immunol. 1999 Dec 15;163(12):6651-8
pubmed: 10586060
Eur Cytokine Netw. 2001 Apr-Jun;12(2):309-15
pubmed: 11399520
Spinal Cord. 2001 Jul;39(7):370-4
pubmed: 11464310
J Comp Neurol. 2002 Dec 16;454(3):213-28
pubmed: 12442313
J Cell Biochem. 2003 Sep 1;90(1):158-69
pubmed: 12938165
J Neurosci. 2004 Mar 3;24(9):2143-55
pubmed: 14999065
Spinal Cord. 2004 Dec;42(12):707-10
pubmed: 15179440
Blood. 2005 May 1;105(9):3512-20
pubmed: 15650055
J Rehabil Med. 2005 May;37(3):129-36
pubmed: 16040468
Nat Med. 2006 Jul;12(7):829-34
pubmed: 16783372
Blood. 2006 Dec 1;108(12):3682-90
pubmed: 16888100
J Cell Biochem. 2007 Aug 1;101(5):1238-51
pubmed: 17226768
J Bone Miner Res. 2008 Aug;23(8):1170-81
pubmed: 18627264
J Bone Joint Surg Am. 2009 May;91(5):1084-91
pubmed: 19411456
J Bone Joint Surg Br. 2009 Nov;91(11):1493-8
pubmed: 19880896
J Clin Invest. 2010 Feb;120(2):582-92
pubmed: 20051625
Nat Cell Biol. 2010 Feb;12(2):153-63
pubmed: 20081841
Blood. 2010 Apr 15;115(15):3109-17
pubmed: 20130243
PLoS One. 2011 Jan 31;6(1):e16632
pubmed: 21304993
Development. 2011 Sep;138(17):3647-56
pubmed: 21828093
PLoS One. 2011;6(8):e23129
pubmed: 21853078
Stem Cells. 2012 Apr;30(4):762-72
pubmed: 22267310
N Engl J Med. 2012 Mar 1;366(9):799-807
pubmed: 22375971
J Head Trauma Rehabil. 2012 Nov-Dec;27(6):443-8
pubmed: 22495100
Brain Inj. 2013;27(7-8):807-11
pubmed: 23730889
Cell Metab. 2013 Aug 6;18(2):251-64
pubmed: 23931756
J Musculoskelet Neuronal Interact. 2014 Mar;14(1):19-28
pubmed: 24583537
Bonekey Rep. 2014 May 14;3:527
pubmed: 24876928
Nat Med. 2014 Oct;20(10):1174-81
pubmed: 25194569
Nat Med. 2014 Oct;20(10):1182-6
pubmed: 25194572
Skeletal Radiol. 2015 Feb;44(2):233-40
pubmed: 25218150
Am J Pathol. 2015 Mar;185(3):765-75
pubmed: 25559270
Cell Signal. 2015 Mar;27(3):555-67
pubmed: 25562430
J Pathol. 2015 Jun;236(2):229-40
pubmed: 25712044
Bone. 2016 Sep;90:159-67
pubmed: 27368930
Biosci Trends. 2017 Jan 16;10(6):460-466
pubmed: 28003635
Spine J. 2017 Oct;17(10):1519-1522
pubmed: 28456672
Bone. 2018 Apr;109:35-42
pubmed: 28526267
Am J Pathol. 2017 Nov;187(11):2536-2545
pubmed: 29029772
JCI Insight. 2017 Nov 2;2(21):
pubmed: 29093266
J Bone Miner Res. 2018 Feb;33(2):365-366
pubmed: 29178621
Mediators Inflamm. 2017;2017:7517350
pubmed: 29362521
Nat Commun. 2018 Apr 18;9(1):1531
pubmed: 29670077
Blood. 2018 Aug 16;132(7):735-749
pubmed: 29945953
Ann Phys Rehabil Med. 2018 Oct 2;:null
pubmed: 30290282
EMBO J. 1995 Mar 15;14(6):1166-75
pubmed: 7720707
Endocrinology. 1996 Apr;137(4):1159-65
pubmed: 8625884
J Biol Chem. 1996 May 31;271(22):12991-8
pubmed: 8662591
Blood. 1997 Jul 1;90(1):165-73
pubmed: 9207450
Biochem J. 1998 Sep 1;334 ( Pt 2):297-314
pubmed: 9716487